# Syntese A/S

Industriholmen 13 2650 Hvidovre CVR No. 13456402

# Annual report 2020

The Annual General Meeting adopted the annual report on 22.03.2021

Lars Peter Brunse Chairman of the General Meeting

# Contents

Entity details	2
Statement by Management	3
Independent auditor's report	4
Management commentary	7
Income statement for 2020	11
Balance sheet at 31.12.2020	12
Statement of changes in equity for 2020	14
Cash flow statement for 2020	15
Notes	16
Accounting policies	22

# **Entity details**

# Entity

Syntese A/S Industriholmen 13 2650 Hvidovre

CVR No.: 13456402 Date of foundation: 31.08.1989 Registered office: Hvidovre Financial year: 01.01.2020 - 31.12.2020 Phone number: +45 36 34 00 30 URL: www.syntese.dk

# **Board of Directors**

Lars Peter Brunse, Chairman Claus Johnsen Jepsen Kim Fonager Jensen Marianne Kock Lizette Bruun

# **Executive Board**

Carsten Hjorth Jensen, adm. dir.

# Bank

Danske Bank, Corporate Banking Denmark Holmens Kanal 2 1092 Copenhagen K

# **Auditors**

Deloitte Statsautoriseret Revisionspartnerselskab Weidekampsgade 6 2300 Copenhagen S

# **Statement by Management**

The Board of Directors and the Executive Board have today considered and approved the annual report of Syntese A/S for the financial year 01.01.2020 - 31.12.2020.

The annual report is presented in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Entity's financial position at 31.12.2020 and of the results of its operations and cash flows for the financial year 01.01.2020 - 31.12.2020.

We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.

We recommend the annual report for adoption at the Annual General Meeting.

Hvidovre, 22.03.2021

**Executive Board** 

**Carsten Hjorth Jensen** adm. dir.

**Board of Directors** 

**Lars Peter Brunse** Chairman **Claus Johnsen Jepsen** 

**Kim Fonager Jensen** 

Marianne Kock

**Lizette Bruun** 

# Independent auditor's report

# To the shareholder of Syntese A/S

# Opinion

We have audited the financial statements of Syntese A/S for the financial year 01.01.2020 - 31.12.2020, which comprise the income statement, balance sheet, statement of changes in equity, cash flow statement and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Entity's financial position at 31.12.2020 and of the results of its operations and cash flows for the financial year 01.01.2020 - 31.12.2020 in accordance with the Danish Financial Statements Act.

## **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of this auditor's report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

# Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Entity's ability to continue as a going concern, for disclosing, as applicable, matters related to going concern, and for using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

#### Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to
  fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence
  that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a
  material misstatement resulting from fraud is higher than for one resulting from error, as fraud may
  involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements, and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures in the notes, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

# Statement on the management commentary

Management is responsible for the management commentary.

Our opinion on the financial statements does not cover the management commentary, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the management commentary and, in doing so, consider whether the management commentary is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the management commentary provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the management commentary is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the management commentary.

Copenhagen, 22.03.2021

# Deloitte

Statsautoriseret Revisionspartnerselskab CVR No. 33963556

# **Flemming Larsen**

State Authorised Public Accountant Identification No (MNE) mne27790

# Management commentary

# **Financial highlights**

	2020	2019	2018	2017	2016
	DKK'000	DKK'000	DKK'000	DKK'000	DKK'000
Key figures					
Revenue	234,689	232,919	210,488	224,258	239,748
Gross profit/loss	56,916	48,210	59,969	66,494	73,773
Operating profit/loss	44,736	37,963	41,727	50,139	56,874
Net financials	(119)	(298)	(376)	(364)	(981)
Profit/loss for the year	34,733	29,378	32,342	38,837	43,543
Total assets	213,602	163,431	156,743	165,235	123,090
Investments in property, plant and equipment	21,135	256,767	13,472	16,222	12,196
Equity	131,132	102,189	101,943	109,601	70,764
Average number of employees	94	93	93	93	90
Ratios					
Gross margin (%)	24.25	20.70	28.49	29.65	30.77
EBIT margin (%)	19.06	16.30	19.82	22.36	23.72
Net margin (%)	14.80	12.61	15.37	17.32	18.16
Return on equity (%)	29.77	28.78	30.58	43.06	69.68
Equity ratio (%)	61.39	62.53	65.04	66.33	57.49
Revenue per employee	2,478	2,478	2,263	2,411	2,644
Return on assets	20.94	23.23	26.62	30.34	46.21

Syntese A/S has merged with the sister company Stamholmen ApS as of 1 January 2020. The comparative figures from 2016 to 2018 has not been changed. The financial highlights for 2019 and 2020 includes the combind figures of both Syntese A/S and Stamholmen ApS as comparative figures have been changed in the annual report.

Financial highlights are defined and calculated in accordance with the current version of "Recommendations & Ratios" issued by the CFA Society Denmark.

**Gross margin (%):** <u>Gross profit/loss \* 100</u> Revenue

**EBIT margin (%):** <u>Operating profit/loss \* 100</u> Revenue **Net margin (%):** <u>Profit/loss for the year \* 100</u> Revenue

Return on equity (%): <u>Profit/loss for the year \* 100</u> Average equity

**Equity ratio (%):** <u>Equity \* 100</u> Total assets

Revenue per employee: Revenue Average number of employees

**Optional ratio 9 (%): Return on assets (%):** <u>Profit before financials \* 100</u> Total assets

## **Primary activities**

The Company's primary activity is to produce the Active Pharmaceutical Ingredient Mesalazine for human use.

In early 2007, the US Food and Drug Administration (FDA) approved the Company, and since then, the Company has been selling its products to the US market. Most company products are sold on the European market.

## **Development in activities and finances**

In December 2020 the board approved to merge Syntese A/S with the sister company Stamholmen ApS. Syntese A/S is the continuing company. The merge has retroactive effect from 1. January 2020. The level of activity remained high in 2020. The Company employed an average staff of 94 in 2020. The COVID-19 crisis has not had a significant influence on the company's result for 2020.

For 2020, the operating profit before net financials and tax is DKK 44,736 thousand (2019: DKK 37,963 thousand). Higher sales, high production volumes and stable raw material prices influenced the operating profit in 2020. The operating profit increased by DKK 6,773 thousand, or 17.8%, from 2019 to 2020.

The profit after interest and tax is DKK 34,733 thousand (2019: 29,378 thousand) and the Company's balance sheet shows equity of DKK 131,132 thousand at 31.12.2020, equalling an equity ratio of 61%.

# Uncertainty relating to recognition and measurement

Nothing to report.

# Unusual circumstances affecting recognition and measurement

Nothing to report.

# Outlook

The Company's level of activity is also expected to be high in 2021. The program of process optimization will continue. The Company's success with this program has resulted in considerable efficiency measures, and there is still room for additional efficiency measures. The COVID-19 crisis is currently not expected to have a significant influence on the outlook for 2021.

## **Particular risks**

The Company produces a product, Mesalazine. The product has a key position in the treatment of Colitis Ulcerosa and Chron's disease. This key position is not expected to change soon.

#### **Intellectual capital resources**

The Company's development department is staffed with highly educated candidates from various universities. The Company is working intensely with process development to minimise the environmental impact and optimise the return from all steps of the process.

# **Environmental performance**

Syntese A/S is a so-called listed undertaking, meaning an undertaking producing pharmaceuticals through a chemical or biological process. Syntese A/S holds an environmental licence for both production and inventories. Also, a separate environmental licence covers the pilot activities, and the Capital Region of Denmark has granted permission to the underground storage tanks.

The main environmental impact of Syntese A/S is its consumption of resources and raw materials, the accrual of waste and process wastewater, and the emission from the two combustion plants. Consumption of resources

includes water, electricity and heating for the entire Company and the use of raw materials for production and development purposes. Process wastewater and waste are key emissions; the environmental impact of which takes the form of accrual of waste and process wastewater, which is transported or discharged for external treatment.

Syntese A/S was certified under DS/EN ISO 14001(environmental management) first time in 2011 and re-certified in 2014 and 2017 (including energy management in 2017). Syntese A/S has been certified under OHSAS 18001 (working environment) since 2013 and was re-certified in 2016. This certification was replaced by DS/EN ISO 45001 (management systems of occupational health and safety) in 2019.

## **Research and development activities**

During the year, the Company continued to develop its processes and technologies to optimise profits and reduce production costs. The programme implemented has had a positive effect in 2019. The programme will continue in the years ahead. Operations have born costs incurred for the process and development activities.

# Events after the balance sheet date

No significant events of significance to the annual report have occurred after the balance date.

# **Income statement for 2020**

		2020	2019
	Notes	DKK'000	DKK '000
Revenue		234,689	232,919
Production costs		(177,773)	(184,709)
Gross profit/loss		56,916	48,210
Administrative expenses		(12,180)	(10,247)
Operating profit/loss		44,736	37,963
Other financial income		64	41
Other financial expenses		(183)	(339)
Profit/loss before tax		44,617	37,665
Tax on profit/loss for the year	3	(9,884)	(8,287)
Profit/loss for the year	4	34,733	29,378

# **Balance sheet at 31.12.2020**

# Assets

	Notes	2020 DKK'000	2019 DKK'000
Acquired licences		2,023	2,098
Intangible assets	5	2,023	2,098
Land and buildings		65,982	62,603
Plant and machinery		31,118	35,570
Other fixtures and fittings, tools and equipment		3,742	3,357
Property, plant and equipment in progress		9,568	0
Property, plant and equipment	6	110,410	101,530
Fixed assets		112,433	103,628
Raw materials and consumables		5,124	4,498
Work in progress		3,488	5,163
Manufactured goods and goods for resale		33,370	27,854
Inventories		41,982	37,515
Trade receivables		2,120	2,465
Receivables from group enterprises		47,819	16,839
Other receivables		7,779	2,340
Prepayments	7	1,469	644
Receivables		59,187	22,288
Current assets		101,169	59,803
Assets		213,602	163,431

# **Equity and liabilities**

	Netze	2020	2019
Contributed capital	Notes 8	<b>DKK'000</b> 2,350	<b>DKK'000</b> 2,340
Retained earnings	0	128,782	2,340 94,049
Proposed dividend		0	5,800
•			
Equity		131,132	102,189
Deferred tax	9	9,486	7,843
Provisions		9,486	7,843
Mortgage debt		4,130	6,212
Lease liabilities		223	508
Other payables		8,974	1,955
Non-current liabilities other than provisions	10	13,327	8,675
Current portion of non-current liabilities other than provisions	10	2,379	2,366
Trade payables		23,109	13,271
Payables to group enterprises		17,748	9,467
Tax payable	11	8,241	10,145
Other payables		8,180	9,475
Current liabilities other than provisions		59,657	44,724
Liabilities other than provisions		72,984	53,399
Equity and liabilities		213,602	163,431
Staff costs	1		
Amortisation, depreciation and impairment losses	2		
Contingent liabilities	13		
Related parties with controlling interest	14		
Group relations	15		

# Statement of changes in equity for 2020

	Contributed capital DKK'000	Retained earnings DKK'000	Proposed dividend DKK'000	Total DKK'000
Equity beginning of year	2,340	94,049	5,800	102,189
Increase of capital	10	0	0	10
Ordinary dividend paid	0	0	(5,800)	(5,800)
Profit/loss for the year	0	34,733	0	34,733
Equity end of year	2,350	128,782	0	131,132

# **Cash flow statement for 2020**

	Notes	2020 DKK'000	2019 DKK'000
Operating profit/loss	Notes	44,736	37,963
Amortisation, depreciation and impairment losses		13,152	12,413
Working capital changes	12	(17,523)	(1,778)
Cash flow from ordinary operating activities		40,365	48,598
Financial income received		64	41
Financial expenses paid		(183)	(339)
Taxes refunded/(paid)		(10,134)	(5,929)
Cash flows from operating activities		<b>30,112</b>	(3,523) <b>42,371</b>
Acquisition etc of intangible assets		(822)	(611)
Acquisition etc of property, plant and equipment		(21,135)	(18,464)
Sale of property, plant and equipment		0	46
Cash flows from investing activities		(21,957)	(19,029)
Free cash flows generated from operations and investments before financing		8,155	23,342
Loans raised		0	1,005
Repayments of loans etc		(2,355)	(2,291)
Dividend paid		(5,800)	(39,000)
Cash flows from financing activities		(8,155)	(40,286)
Increase/decrease in cash and cash equivalents		0	(16,944)
Cash and cash equivalents beginning of year		0	16,944
Cash and cash equivalents end of year		0	0

Cash and cash equivalents at year-end are composed of:

# Notes

# **1 Staff costs**

	2020	2019
	DKK'000	DKK'000
Wages and salaries	59,781	53,616
Pension costs	6,741	6,322
Other social security costs	824	592
	67,346	60,530
Average number of full-time employees	94	94

Pursuant til section 98b(3) of the Danish Financial Statement Act, the Company has omitted to disclose Management's remuneration.

	2020	2019 DKK'000
	DKK'000	
Wages and salaries, pension costs and other social security costs are		
recognised in the following items:		
Production costs	58,944	54,075
Administrative costs	8,402	6,455
	67,346	60,530

# 2 Depreciation, amortisation and impairment losses

	2020 DKK'000	2019
		DKK'000
Amortisation of intangible assets	897	921
Depreciation of property, plant and equipment	12,255	11,492
Profit/loss from sale of intangible assets and property, plant and equipment	0	(3)
	13,152	12,410

	2020	2019 DKK'000
	DKK'000	
Depreciation, amortisation and impairment losses are recognised in		
the following items:		
Production costs	12,293	11,611
Administrative costs	859	799
	13,152	12,410
3 Tax on profit/loss for the year		
	2020 DKK'000	2019 DKK'000
Current tax	8,241	10,145
Change in deferred tax	1,643	(1,858)
	9,884	8,287
4 Proposed distribution of profit and loss		
	2020	2019
	DKK'000	DKK'000
Ordinary dividend for the financial year	0	5,800

	34,733	29,378
Retained earnings	34,733	23,578
Ordinary dividend for the financial year	0	5,800

# 5 Intangible assets

	Acquired
	licences
	DKK'000
Cost beginning of year	11,764
Additions	822
Cost end of year	12,586
Amortisation and impairment losses beginning of year	(9,666)
Amortisation for the year	(897)
Amortisation and impairment losses end of year	(10,563)
Carrying amount end of year	2,023

# 6 Property, plant and equipment

	Land and buildings DKK'000	Plant and machinery DKK'000	Other fixtures and fittings, tools and equipment DKK'000	Property, plant and equipment in progress DKK'000
Cost beginning of year	129,850	163,464	5,308	0
Additions	6,958	3,126	1,483	9,568
Cost end of year	136,808	166,590	6,791	9,568
Depreciation and impairment losses beginning of year	(67,247)	(127,894)	(1,951)	0
Depreciation for the year	(3,579)	(7,578)	(1,098)	0
Depreciation and impairment losses end of year	(70,826)	(135,472)	(3,049)	0
Carrying amount end of year	65,982	31,118	3,742	9,568

Other fixtures and fittings, tools and equipment include lease contracts at a book value of DKK 504 thousand.

# 7 Prepayments

Prepayments include prepaid expenses such as insurance.

# 8 Share capital

		Nominal value
	Number	DKK'000
Ordinary shares	2,350	2,350
	2,350	2,350

# 9 Deferred tax

	2020	2019
Changes during the year	DKK'000	DKK'000
Beginning of year	7,843	9,771
Recognised in the income statement	1,643	(1,928)
End of year	9,486	7,843

# 10 Non-current liabilities other than provisions

	Due within 12 months 2020 DKK'000	Due within 12 months 2019 DKK'000	Due after more than 12 months 2020 DKK'000
Mortgage debt	2,082	2,082	4,130
Lease liabilities	297	284	223
Other payables	0	0	8,974
	2,379	2,366	13,327

# **11 Tax payable**

Income tax payable consists of joint taxation contribution.

# 12 Changes in working capital

	2020	2019
	DKK'000	DKK'000
Increase/decrease in inventories	(4,467)	11,484
Increase/decrease in receivables	(36,899)	(10,848)
Increase/decrease in trade payables etc	23,843	(2,414)
	(17,523)	(1,778)

# **13 Contingent liabilities**

The Entity participates in a Danish joint taxation arrangement in which Ferring Pharmaceuticals A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Company is therefore liable for income taxes etc for the jointly taxed companies and for obligations, if any, relating to the withholding of tax on interest, royalties and dividend for the jointly taxed companies.

The total known net liability of the jointly taxed companies under the joint taxation arrangement is evident from the administration company's financial statements.

The Company has contractual obligations regarding fixed assets of DKK 5 million.

# 14 Related parties with controlling interest

Below-listed companies, performing a management function and/or, have a controlling interest:

# **Parent Foundation:**

Dr. Frederik Paulsen Foundation Thistle House, 4 Burnaby Street Hamilton HM11 Bermuda

# **Intermediate Parent:**

Insula Corporation S.à r.l. 7 Rue Robert Stümper, L-2557 Luxembourg

Insula (Holding) S.à r.l. 7 Rue Robert Stümper, L-2557 Luxembourg

Isles (Holding) B.V. Siriusdreef 41 2132 WT Hoofddorp The Netherlands

Isles B.V. Siriusdreef 41 2132 WT Hoofddorp The Netherlands

Ferring Holding S.A. Chemin De La Vergognausaz 50 1162 Saint-Prex, Vaud Switzerland

# **Immediate Parent:**

Ferring B.V. Polarisavenue 144 2132 JX Hoofddorp The Netherlands

# **15 Group relations**

Name and registered office of the Parent preparing consolidated financial statements for the largest group: Insula Corporation S.á.r.l.\* 7 Rue Robert Stümper, L-2557 Luxembourg

Name and registered office of the Parent preparing consolidated financial statements for the smallest group: Ferring Holding S.A. Chemin De La Vergognausaz 50 1162 Saint-Prex, Vaud Switzerland

\*The consolidated Financial Statement is available on Ferring.com.

# **Accounting policies**

# **Reporting class**

This annual report has been prepared in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium).

The accounting policies applied to these financial statements are consistent with those applied last year.

## **Recognition and measurement**

Assets are recognised in the balance sheet when it is probable as a result of a prior event that future economic benefits will flow to the Entity, and the value of the asset can be measured reliably.

Liabilities are recognised in the balance sheet when the Entity has a legal or constructive obligation as a result of a prior event, and it is probable that future economic benefits will flow out of the Entity, and the value of the liability can be measured reliably.

On initial recognition, assets and liabilities are measured at cost. Measurement subsequent to initial recognition is effected as described below for each financial statement item.

Anticipated risks and losses that arise before the time of presentation of the annual report and that confirm or invalidate affairs and conditions existing at the balance sheet date are considered at recognition and measurement.

Income is recognised in the income statement when earned, whereas costs are recognised by the amounts attributable to this financial year.

# **Business combinations**

The uniting-of-interests method is applied on acquisition of enterprises, mergers, demergers, contributions of assets and exchanges of shares, etc where the enterprises concerned are controlled by the Parent. Under the uniting-of-interests method, the acquiree's assets and liabilities are recognised at their carrying amounts, adjusted for any differences in accounting policies. The difference between the consideration agreed and the carrying amount of the acquiree is recognised in equity. The comparative figures are restated.

# **Foreign currency translation**

On initial recognition, foreign currency transactions are translated applying the exchange rate at the transaction date. Receivables, payables and other monetary items denominated in foreign currencies that have not been settled at the balance sheet date are translated using the exchange rate at the balance sheet date. Exchange differences that arise between the rate at the transaction date and the rate in effect at the payment date, or the rate at the balance sheet date, are recognised in the income statement as financial income or financial expenses.

## **Derivative financial instruments**

On initial recognition in the balance sheet, derivative financial instruments are measured at cost and subsequently at fair value. Derivative financial instruments are recognised under other receivables or other payables.

For derivative financial instruments that do not comply with the requirements for being treated as hedging

instruments, changes in fair value are recognised currently in the income statement as financial income or financial expenses.

# **Income statement**

# Revenue

Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.

# **Production costs**

Production costs comprise expenses incurred to earn revenue for the financial year. Production costs comprise direct and indirect costs for raw materials and consumables, wages and salaries, rent and lease as well as amortisation, depreciation and impairment losses relating to intangible assets and property, plant and equipment included in the production process. In addition, the item includes ordinary write-down of inventories.

Production costs related to work in progress are recognised when incurred.

Production costs also include recognised insurance costs, costs related to development projects that do not meet the criteria for recognition in the balance sheet as well as amortisation of recognised development projects. In addition, provisions for loss on contract work in progress are recognised under production costs.

## Administrative expenses

Administrative expenses comprise expenses incurred for the Entity's administrative functions, including wages and salaries for administrative staff and Management, stationery and office supplies, and amortisation, depreciation and impairment losses relating to intangible assets and property, plant and equipment used for administration of the Entity.

# Other financial income

Other financial income comprises interest, realised and unrealised exchange gains on transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme.

#### Other financial expenses

Other financial expenses comprises interest expenses, realised and unrealised exchange losses on transactions in foreign currencies as well as tax surcharge under the Danish Tax Prepayment Scheme.

## Tax on profit/loss for the year

Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.

The Entity is jointly taxed with all Danish group enterprises. The current Danish income tax is allocated among the jointly taxed entities proportionally to their taxable income (full allocation with a refund concerning tax losses).

## **Balance sheet**

# Intellectual property rights etc

Intellectual property rights etc consist of software and licences. Intellectual property rights acquired are measured at cost less accumulated amortisation. Software is amortised on a straight line basis over its useful life not exceeding four years, and licenses are amortised over the term of the agreement.

Intellectual property rights etc are written down to the lower of recoverable amount and carrying amount.

# Property, plant and equipment

Land and buildings, plant and machinery as well as other fixtures and fittings, tools and equipment are measured at cost less accumulated depreciation and impairment losses. Land is not depreciated.

Cost comprises the acquisition price, costs directly attributable to the acquisition and preparation costs of the asset until the time when it is ready to be put into operation. For self-constructed assets, cost comprises direct and indirect costs of materials, components, subsuppliers and labour costs.

The basis of depreciation is cost less estimated residual value after the end of useful life. Straight-line depreciation is made on the basis of the following estimated useful lives of the assets:

Buildings	20-40 years
Plant and machinery	5-15 years
Other fixtures and fittings, tools and equipment	3-5 years

For assets subject to lease agreements, the depreciation period cannot exceed the contract period.

Estimated useful lives and residual values are reassessed annually.

Items of property, plant and equipment are written down to the lower of recoverable amount and carrying amount.

# Inventories

Inventories are measured at the lower of cost using the FIFO method and net realisable value.

Cost consists of purchase price plus delivery costs. Cost of manufactured goods and work in progress consists of costs of raw materials, consumables, direct labour costs and indirect production costs.

Indirect production costs comprise indirect materials and labour costs, costs of maintenance of, depreciation of and impairment losses relating to machinery, factory buildings and equipment used in the manufacturing process, and costs of factory administration and management. Finance costs are not included in cost.

The net realisable value of inventories is calculated as the estimated selling price less completion costs and costs incurred to execute sale.

# Receivables

Receivables are measured at amortised cost, usually equalling nominal value, less writedowns for bad and doubtful debts.

# Prepayments

Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.

# Dividend

Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity.

# **Deferred tax**

Deferred tax is recognised on all temporary differences between the carrying amount and the tax-based value of assets and liabilities, for which the tax-based value is calculated based on the planned use of each asset.

Deferred tax assets, including the tax base of tax loss carryforwards, are recognised in the balance sheet at their estimated realisable value, either as a set-off against deferred tax liabilities or as net tax assets.

# Mortgage debt

At the time of borrowing, mortgage debt to mortgage credit institutions is measured at cost which corresponds to the proceeds received less transaction costs incurred. Mortgage debt is subsequently measured at amortised cost. This means that the difference between the proceeds at the time of borrowing and the nominal repayable amount of the loan is recognised in the income statement as a financial expense over the term of the loan applying the effective interest method.

# Lease liabilities

Lease commitments relating to assets held under finance leases are recognised in the balance sheet as liabilities other than provisions, and, at the time of inception of the lease, measured at the present value of future lease payments. Subsequent to initial recognition, lease commitments are measured at amortised cost. The difference between present value and nominal amount of the lease payments is recognised in the income statement as a financial expense over the term of the leases.

# **Operating leases**

Lease payments on operating leases are recognised on a straight-line basis in the income statement over the term of the lease.

# **Other financial liabilities**

Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.

# Tax receivable or payable

Current tax receivable or payable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax.

# **Cash flow statement**

The cash flow statement shows cash flows from operating, investing and financing activities, and cash and cash equivalents at the beginning and the end of the financial year.

Cash flows from operating activities are presented using the indirect method and calculated as the operating profit/loss adjusted for non-cash operating items, working capital changes and income taxes paid.

Cash flows from investing activities comprise payments in connection with activities and fixed asset investments, and purchase, development, improvement and sale, etc of intangible assets and property, plant and equipment, including acquisition of assets held under finance leases.

Cash flows from financing activities comprise changes in the size or composition of the contributed capital and related costs as well as the raising of loans, inception of finance leases, repayments of interest-bearing debt, purchase of treasury shares and payment of dividend.

Cash and cash equivalents comprise cash and short-term securities with an insignificant price risk less short-term bank debt.